25 XP   0   0   10

Rani Therapeutics Holdings Inc
Buy, Hold or Sell?

Let's analyse Rani Therapeutics Holdings Inc together

PenkeI guess you are interested in Rani Therapeutics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rani Therapeutics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Rani Therapeutics Holdings Inc

I send you an email if I find something interesting about Rani Therapeutics Holdings Inc.

Quick analysis of Rani Therapeutics Holdings Inc (30 sec.)










What can you expect buying and holding a share of Rani Therapeutics Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
6.3%

What is your share worth?

Current worth
$0.98
Expected worth in 1 year
$-0.89
How sure are you?
18.8%

+ What do you gain per year?

Total Gains per Share
$-1.86
Return On Investment
-27.8%

For what price can you sell your share?

Current Price per Share
$6.70
Expected price per share
$5.79 - $8.99
How sure are you?
50%

1. Valuation of Rani Therapeutics Holdings Inc (5 min.)




Live pricePrice per Share (EOD)

$6.70

Intrinsic Value Per Share

$-22.46 - $-26.35

Total Value Per Share

$-21.48 - $-25.37

2. Growth of Rani Therapeutics Holdings Inc (5 min.)




Is Rani Therapeutics Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$25.4m$92.4m-$49.9m-117.6%

How much money is Rani Therapeutics Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$8.4m-$15.8m$7.3m86.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Rani Therapeutics Holdings Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#546 / 1007

Most Revenue
#838 / 1007

Most Profit
#527 / 1007

Most Efficient
#281 / 1007

What can you expect buying and holding a share of Rani Therapeutics Holdings Inc? (5 min.)

Welcome investor! Rani Therapeutics Holdings Inc's management wants to use your money to grow the business. In return you get a share of Rani Therapeutics Holdings Inc.

What can you expect buying and holding a share of Rani Therapeutics Holdings Inc?

First you should know what it really means to hold a share of Rani Therapeutics Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Rani Therapeutics Holdings Inc is $6.7. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rani Therapeutics Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rani Therapeutics Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.98. Based on the TTM, the Book Value Change Per Share is $-0.47 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.46 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rani Therapeutics Holdings Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.27-4.1%-0.41-6.1%-0.59-8.8%-0.35-5.3%-0.35-5.3%
Usd Book Value Change Per Share-0.36-5.4%-0.47-7.0%-0.46-6.8%0.060.9%0.060.9%
Usd Dividend Per Share0.000.0%0.000.0%0.142.1%0.040.5%0.040.5%
Usd Total Gains Per Share-0.36-5.4%-0.47-7.0%-0.31-4.7%0.101.4%0.101.4%
Usd Price Per Share3.32-3.69-9.83-5.52-5.52-
Price to Earnings Ratio-3.05--2.37--6.02--5.69--5.69-
Price-to-Total Gains Ratio-9.22--8.07--1.92--7.84--7.84-
Price to Book Ratio3.40-2.36-2.72-1.71-1.71-
Price-to-Total Gains Ratio-9.22--8.07--1.92--7.84--7.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.7
Number of shares149
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.470.06
Usd Total Gains Per Share-0.470.10
Gains per Quarter (149 shares)-69.4614.42
Gains per Year (149 shares)-277.8657.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-278-288213648
20-556-5664373106
30-834-84464109164
40-1111-112285146222
50-1389-1400106182280
60-1667-1678128218338
70-1945-1956149255396
80-2223-2234170291454
90-2501-2512191328512
100-2779-2790213364570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%2.011.03.012.5%2.011.03.012.5%2.011.03.012.5%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.015.06.3%1.00.015.06.3%1.00.015.06.3%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%3.010.03.018.8%3.010.03.018.8%3.010.03.018.8%

Fundamentals of Rani Therapeutics Holdings Inc

About Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.

Fundamental data was last updated by Penke on 2024-04-12 16:13:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Rani Therapeutics Holdings Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rani Therapeutics Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,382.9%+1,382.9%
5Y-1,382.9%10Y-1,382.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.4%+282.4%
5Y-1,382.9%-434.0%-948.9%
10Y-1,382.9%-584.8%-798.1%
1.1.2. Return on Assets

Shows how efficient Rani Therapeutics Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • -12.3% Return on Assets means that Rani Therapeutics Holdings Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rani Therapeutics Holdings Inc:

  • The MRQ is -12.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.3%TTM-11.3%-1.0%
TTM-11.3%YOY-14.6%+3.3%
TTM-11.3%5Y-9.5%-1.8%
5Y-9.5%10Y-9.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.3%-13.2%+0.9%
TTM-11.3%-12.7%+1.4%
YOY-14.6%-11.5%-3.1%
5Y-9.5%-13.8%+4.3%
10Y-9.5%-15.5%+6.0%
1.1.3. Return on Equity

Shows how efficient Rani Therapeutics Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • -55.2% Return on Equity means Rani Therapeutics Holdings Inc generated $-0.55 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rani Therapeutics Holdings Inc:

  • The MRQ is -55.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -43.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-55.2%TTM-43.4%-11.8%
TTM-43.4%YOY-36.2%-7.2%
TTM-43.4%5Y-22.0%-21.3%
5Y-22.0%10Y-22.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-55.2%-16.7%-38.5%
TTM-43.4%-15.9%-27.5%
YOY-36.2%-14.7%-21.5%
5Y-22.0%-19.2%-2.8%
10Y-22.0%-20.0%-2.0%

1.2. Operating Efficiency of Rani Therapeutics Holdings Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rani Therapeutics Holdings Inc is operating .

  • Measures how much profit Rani Therapeutics Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,136.1%+1,136.1%
5Y-1,136.1%10Y-1,136.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--291.9%+291.9%
5Y-1,136.1%-485.6%-650.5%
10Y-1,136.1%-610.8%-525.3%
1.2.2. Operating Ratio

Measures how efficient Rani Therapeutics Holdings Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y11.358-11.358
5Y11.35810Y11.3580.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.791-3.791
5Y11.3585.675+5.683
10Y11.3587.558+3.800

1.3. Liquidity of Rani Therapeutics Holdings Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rani Therapeutics Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.33 means the company has $6.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 6.327. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.385. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.327TTM11.385-5.058
TTM11.385YOY19.897-8.511
TTM11.3855Y14.252-2.866
5Y14.25210Y14.2520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3273.877+2.450
TTM11.3854.178+7.207
YOY19.8975.343+14.554
5Y14.2526.135+8.117
10Y14.2526.468+7.784
1.3.2. Quick Ratio

Measures if Rani Therapeutics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Quick Ratio of 11.51 means the company can pay off $11.51 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 11.505. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 20.528. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.505TTM20.528-9.023
TTM20.528YOY25.737-5.209
TTM20.5285Y17.911+2.617
5Y17.91110Y17.9110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.5053.514+7.991
TTM20.5283.998+16.530
YOY25.7375.380+20.357
5Y17.9116.135+11.776
10Y17.9116.434+11.477

1.4. Solvency of Rani Therapeutics Holdings Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rani Therapeutics Holdings Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rani Therapeutics Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.56 means that Rani Therapeutics Holdings Inc assets are financed with 56.1% credit (debt) and the remaining percentage (100% - 56.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 0.561. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.463. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.561TTM0.463+0.098
TTM0.463YOY0.152+0.310
TTM0.4635Y0.624-0.162
5Y0.62410Y0.6240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5610.339+0.222
TTM0.4630.336+0.127
YOY0.1520.271-0.119
5Y0.6240.368+0.256
10Y0.6240.388+0.236
1.4.2. Debt to Equity Ratio

Measures if Rani Therapeutics Holdings Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 252.4% means that company has $2.52 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rani Therapeutics Holdings Inc:

  • The MRQ is 2.524. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.789. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.524TTM1.789+0.735
TTM1.789YOY0.410+1.378
TTM1.7895Y0.560+1.229
5Y0.56010Y0.5600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5240.388+2.136
TTM1.7890.403+1.386
YOY0.4100.340+0.070
5Y0.5600.430+0.130
10Y0.5600.463+0.097

2. Market Valuation of Rani Therapeutics Holdings Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rani Therapeutics Holdings Inc generates.

  • Above 15 is considered overpriced but always compare Rani Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A PE ratio of -3.05 means the investor is paying $-3.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rani Therapeutics Holdings Inc:

  • The EOD is -6.145. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.045. Based on the earnings, the company is expensive. -2
  • The TTM is -2.369. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.145MRQ-3.045-3.100
MRQ-3.045TTM-2.369-0.677
TTM-2.369YOY-6.017+3.648
TTM-2.3695Y-5.686+3.318
5Y-5.68610Y-5.6860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.145-2.281-3.864
MRQ-3.045-2.599-0.446
TTM-2.369-2.674+0.305
YOY-6.017-4.133-1.884
5Y-5.686-6.258+0.572
10Y-5.686-6.270+0.584
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rani Therapeutics Holdings Inc:

  • The EOD is -3.449. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.709. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.875. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.449MRQ-1.709-1.740
MRQ-1.709TTM-1.875+0.165
TTM-1.875YOY-5.721+3.847
TTM-1.8755Y-3.119+1.244
5Y-3.11910Y-3.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.449-2.903-0.546
MRQ-1.709-3.323+1.614
TTM-1.875-3.552+1.677
YOY-5.721-5.592-0.129
5Y-3.119-8.378+5.259
10Y-3.119-8.875+5.756
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rani Therapeutics Holdings Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.40 means the investor is paying $3.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Rani Therapeutics Holdings Inc:

  • The EOD is 6.857. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.398. Based on the equity, the company is fair priced.
  • The TTM is 2.358. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD6.857MRQ3.398+3.459
MRQ3.398TTM2.358+1.040
TTM2.358YOY2.715-0.357
TTM2.3585Y1.707+0.651
5Y1.70710Y1.7070.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.8571.911+4.946
MRQ3.3982.116+1.282
TTM2.3582.097+0.261
YOY2.7152.885-0.170
5Y1.7073.556-1.849
10Y1.7073.959-2.252
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Rani Therapeutics Holdings Inc.

3.1. Institutions holding Rani Therapeutics Holdings Inc

Institutions are holding 13.425% of the shares of Rani Therapeutics Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc2.56650.0001668347-742-0.1109
2023-12-31United Services Automobile Association1.84830.035448130000
2023-12-31Alphabet Inc1.72230.06944849200
2023-12-31Bank of America Corp0.43880114259-92862-44.8347
2023-12-31Geode Capital Management, LLC0.4363011362900
2023-12-31BlackRock Inc0.244206358300
2023-12-31Lasry Marc0.24150.30836288700
2023-12-31King Luther Capital Management Corp0.21550.00095612900
2023-12-31Bridgeway Capital Management, LLC0.19780.00375150000
2023-12-31Stifel Financial Corp0.1930.000250266-91638-64.5775
2023-12-31Motco0.18480.01024812900
2023-12-31Renaissance Technologies Corp0.16780.000243700-7300-14.3137
2023-12-31Brown Advisory Holdings Inc0.13020.00023391100
2023-12-31State Street Corporation0.129603374200
2023-12-31Lafayette Investments, Inc.0.07640.01641989300
2023-12-31RSM US WEALTH MANAGEMENT LLC0.07610.00181981300
2023-12-31Northern Trust Corp0.074601942100
2023-12-31Prime Capital Investment Advisors, LLC0.06410.00081668200
2023-12-31Activest Wealth Management0.03760.018980000
2023-12-31Islay Capital Management, LLC0.03690.0246961100
Total 9.08230.48982365094-192542-8.1%

3.2. Funds holding Rani Therapeutics Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv1.99190.000151870200
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.55560.000514467400
2024-02-29Fidelity Extended Market Index0.28340.000773791-358-0.4828
2023-12-31Bridgeway Ultra-Small Company Market0.19780.0925150000
2023-09-30BlackRock Extended Mkt Composite0.07230.00031882100
2024-02-29Fidelity Total Market Index0.07040.00011832400
2024-02-29Vanguard Balanced Index Inv0.06840.00011780900
2024-02-29Fidelity Series Total Market Index0.06530.00011699600
2024-03-31BlackRock Extended Equity Market K0.06310.00041642660.0365
2024-02-29Fidelity Nasdaq Composite Index0.05730.00041491500
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.05470.00021424800
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.05470.000114248-507907-97.2713
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04120.00061072100
2023-12-31Northern Trust Extended Eq Market Idx0.04120.00061072100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03050.0004795000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02450.00046385120.1883
2024-02-29Spartan Total Market Index Pool E0.01530.0001398000
2024-02-29LUX IM Global Medtech HX0.01510.0063393200
2024-02-29Vanguard U.S. Eq Idx £ Acc0.0150.0001390200
2024-02-29Spartan Extended Market Index Pool E0.01080.0004280435814.6361
Total 3.72850.1039970849-507889-52.3%

3.3. Insider Transactions

Insiders are holding 48.416% of the shares of Rani Therapeutics Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-06Talat ImranBUY100002.27
2023-12-04Talat ImranBUY50002.57
2023-11-29Talat ImranBUY200002.05
2023-11-24Cortes Isidoro Alfonso QuirogaSELL52651652.01
2023-11-16Maulik NanavatyBUY5001.98
2023-05-11South Cone Investments LimitedBUY26103.87
2023-05-08South Cone Investments LimitedBUY44204.46
2023-05-03South Cone Investments LimitedBUY20404.81
2023-04-28South Cone Investments LimitedBUY21734.71
2023-04-24South Cone Investments LimitedBUY42804.67
2023-04-20South Cone Investments LimitedBUY18505.32
2023-04-18South Cone Investments LimitedBUY18505.37
2023-04-14South Cone Investments LimitedBUY19015.27
2023-04-12South Cone Investments LimitedBUY35775.48

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Rani Therapeutics Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.360-0.466+29%-0.457+27%0.061-690%0.061-690%
Book Value Per Share--0.9771.632-40%3.551-72%1.347-27%1.347-27%
Current Ratio--6.32711.385-44%19.897-68%14.252-56%14.252-56%
Debt To Asset Ratio--0.5610.463+21%0.152+268%0.624-10%0.624-10%
Debt To Equity Ratio--2.5241.789+41%0.410+515%0.560+351%0.560+351%
Dividend Per Share----0%0.143-100%0.036-100%0.036-100%
Eps---0.273-0.406+49%-0.587+115%-0.355+30%-0.355+30%
Free Cash Flow Per Share---0.486-0.504+4%-0.462-5%-0.345-29%-0.345-29%
Free Cash Flow To Equity Per Share---0.482-0.501+4%-0.183-62%0.092-626%0.092-626%
Gross Profit Margin--1.0321.008+2%1.000+3%1.002+3%1.002+3%
Intrinsic Value_10Y_max---26.346--------
Intrinsic Value_10Y_min---22.462--------
Intrinsic Value_1Y_max---1.781--------
Intrinsic Value_1Y_min---1.749--------
Intrinsic Value_3Y_max---6.007--------
Intrinsic Value_3Y_min---5.721--------
Intrinsic Value_5Y_max---11.021--------
Intrinsic Value_5Y_min---10.173--------
Market Cap174473360.000+50%86455456.00096188205.000-10%255915962.000-66%143639425.250-40%143639425.250-40%
Net Profit Margin----0%-0%-13.8290%-13.8290%
Operating Margin----0%-0%-11.3610%-11.3610%
Operating Ratio----0%-0%11.358-100%11.358-100%
Pb Ratio6.857+50%3.3982.358+44%2.715+25%1.707+99%1.707+99%
Pe Ratio-6.145-102%-3.045-2.369-22%-6.017+98%-5.686+87%-5.686+87%
Price Per Share6.700+50%3.3203.694-10%9.828-66%5.516-40%5.516-40%
Price To Free Cash Flow Ratio-3.449-102%-1.709-1.875+10%-5.721+235%-3.119+82%-3.119+82%
Price To Total Gains Ratio-18.609-102%-9.221-8.070-12%-1.919-79%-7.842-15%-7.842-15%
Quick Ratio--11.50520.528-44%25.737-55%17.911-36%17.911-36%
Return On Assets---0.123-0.113-8%-0.146+19%-0.095-23%-0.095-23%
Return On Equity---0.552-0.434-21%-0.362-34%-0.220-60%-0.220-60%
Total Gains Per Share---0.360-0.466+29%-0.314-13%0.097-472%0.097-472%
Usd Book Value--25443000.00042505000.000-40%92477250.000-72%27357500.000-7%27357500.000-7%
Usd Book Value Change Per Share---0.360-0.466+29%-0.457+27%0.061-690%0.061-690%
Usd Book Value Per Share--0.9771.632-40%3.551-72%1.347-27%1.347-27%
Usd Dividend Per Share----0%0.143-100%0.036-100%0.036-100%
Usd Eps---0.273-0.406+49%-0.587+115%-0.355+30%-0.355+30%
Usd Free Cash Flow---12645000.000-13116250.000+4%-12033500.000-5%-9344375.000-26%-9344375.000-26%
Usd Free Cash Flow Per Share---0.486-0.504+4%-0.462-5%-0.345-29%-0.345-29%
Usd Free Cash Flow To Equity Per Share---0.482-0.501+4%-0.183-62%0.092-626%0.092-626%
Usd Market Cap174473360.000+50%86455456.00096188205.000-10%255915962.000-66%143639425.250-40%143639425.250-40%
Usd Price Per Share6.700+50%3.3203.694-10%9.828-66%5.516-40%5.516-40%
Usd Profit---7098000.000-8492500.000+20%-15836250.000+123%-9525812.500+34%-9525812.500+34%
Usd Revenue----0%-0%28812.500-100%28812.500-100%
Usd Total Gains Per Share---0.360-0.466+29%-0.314-13%0.097-472%0.097-472%
 EOD+5 -3MRQTTM+15 -15YOY+8 -245Y+7 -2710Y+7 -27

4.2. Fundamental Score

Let's check the fundamental score of Rani Therapeutics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.145
Price to Book Ratio (EOD)Between0-16.857
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.505
Current Ratio (MRQ)Greater than16.327
Debt to Asset Ratio (MRQ)Less than10.561
Debt to Equity Ratio (MRQ)Less than12.524
Return on Equity (MRQ)Greater than0.15-0.552
Return on Assets (MRQ)Greater than0.05-0.123
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Rani Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.320
Ma 20Greater thanMa 505.478
Ma 50Greater thanMa 1004.234
Ma 100Greater thanMa 2003.778
OpenGreater thanClose6.610
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets57,916
Total Liabilities32,473
Total Stockholder Equity12,866
 As reported
Total Liabilities 32,473
Total Stockholder Equity+ 12,866
Total Assets = 57,916

Assets

Total Assets57,916
Total Current Assets50,547
Long-term Assets7,369
Total Current Assets
Cash And Cash Equivalents 6,364
Short-term Investments 42,675
Net Receivables 200
Other Current Assets 1,308
Total Current Assets  (as reported)50,547
Total Current Assets  (calculated)50,547
+/-0
Long-term Assets
Property Plant Equipment 6,823
Long-term Assets Other 546
Long-term Assets  (as reported)7,369
Long-term Assets  (calculated)7,369
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,989
Long-term Liabilities24,484
Total Stockholder Equity12,866
Total Current Liabilities
Short-term Debt 5,615
Short Long Term Debt 4,897
Accounts payable 648
Other Current Liabilities 1,726
Total Current Liabilities  (as reported)7,989
Total Current Liabilities  (calculated)12,886
+/- 4,897
Long-term Liabilities
Long term Debt 24,484
Capital Lease Obligations 718
Long-term Liabilities  (as reported)24,484
Long-term Liabilities  (calculated)25,202
+/- 718
Total Stockholder Equity
Common Stock5
Retained Earnings -72,889
Accumulated Other Comprehensive Income -12
Other Stockholders Equity 85,762
Total Stockholder Equity (as reported)12,866
Total Stockholder Equity (calculated)12,866
+/-0
Other
Capital Stock5
Cash and Short Term Investments 49,039
Common Stock Shares Outstanding 25,874
Liabilities and Stockholders Equity 57,916
Net Debt 23,735
Net Invested Capital 42,247
Net Working Capital 42,858
Property Plant and Equipment Gross 10,494
Short Long Term Debt Total 30,099



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
79,415
82,077
77,321
136,958
124,207
115,309
104,344
108,202
108,027
96,446
83,507
70,436
57,916
57,91670,43683,50796,446108,027108,202104,344115,309124,207136,95877,32182,07779,415000
   > Total Current Assets 
0
0
0
74,945
76,802
69,479
132,365
119,595
109,260
97,993
100,720
100,924
89,038
76,374
63,222
50,547
50,54763,22276,37489,038100,924100,72097,993109,260119,595132,36569,47976,80274,945000
       Cash And Cash Equivalents 
0
0
0
73,058
76,662
69,314
129,743
117,453
107,839
97,181
27,219
27,007
18,984
7,552
4,972
6,364
6,3644,9727,55218,98427,00727,21997,181107,839117,453129,74369,31476,66273,058000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
70,952
71,475
67,803
67,054
55,554
42,675
42,67555,55467,05467,80371,47570,9520000000000
       Net Receivables 
0
0
0
1,720
0
0
0
0
0
0
0
0
125
200
200
200
200200200125000000001,720000
       Other Current Assets 
0
0
0
167
140
165
2,622
2,142
1,421
812
2,549
1,942
1,751
1,768
2,696
1,308
1,3082,6961,7681,7511,9422,5498121,4212,1422,622165140167000
   > Long-term Assets 
0
0
0
4,470
5,275
7,842
4,593
4,612
6,049
6,351
7,482
7,103
7,408
7,133
7,214
7,369
7,3697,2147,1337,4087,1037,4826,3516,0494,6124,5937,8425,2754,470000
       Property Plant Equipment 
0
0
0
4,470
4,490
4,430
4,593
4,612
6,049
6,351
6,982
7,103
7,408
7,133
7,214
6,823
6,8237,2147,1337,4087,1036,9826,3516,0494,6124,5934,4304,4904,470000
       Other Assets 
0
0
0
0
785
3,412
0
0
0
0
500
0
0
0
0
0
0000050000003,4127850000
> Total Liabilities 
0
0
0
192,754
200,548
200,995
5,250
2,640
4,665
5,690
21,595
34,023
34,857
35,338
35,617
32,473
32,47335,61735,33834,85734,02321,5955,6904,6652,6405,250200,995200,548192,754000
   > Total Current Liabilities 
0
0
0
5,308
7,086
9,355
5,250
2,640
4,156
5,349
7,186
4,815
5,150
5,735
7,345
7,989
7,9897,3455,7355,1504,8157,1865,3494,1562,6405,2509,3557,0865,308000
       Short-term Debt 
0
0
0
1,359
1,946
3,884
0
0
650
658
984
1,006
923
856
2,010
5,615
5,6152,0108569231,006984658650003,8841,9461,359000
       Short Long Term Debt 
0
0
0
1,359
1,946
3,884
0
0
0
0
0
0
0
0
1,222
4,897
4,8971,222000000003,8841,9461,359000
       Accounts payable 
0
0
0
537
943
1,667
1,311
1,080
1,265
1,440
1,790
1,460
1,511
1,037
1,405
648
6481,4051,0371,5111,4601,7901,4401,2651,0801,3111,667943537000
       Other Current Liabilities 
0
0
0
695
2,236
353
3,939
1,560
2,241
3,251
4,412
2,349
2,716
531
3,930
1,726
1,7263,9305312,7162,3494,4123,2512,2411,5603,9393532,236695000
   > Long-term Liabilities 
0
0
0
187,446
193,462
191,640
0
1,080
509
341
14,409
29,208
29,707
29,603
28,272
24,484
24,48428,27229,60329,70729,20814,4093415091,0800191,640193,462187,446000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
14,091
29,149
29,207
0
0
0
00029,20729,14914,0910000000000
       Deferred Long Term Liability 
0
0
0
0
785
3,412
0
0
0
0
0
0
0
0
0
0
00000000003,4127850000
> Total Stockholder Equity
0
0
0
-113,339
-118,471
-123,674
51,366
47,411
53,384
47,813
42,194
36,855
30,722
24,094
17,553
12,866
12,86617,55324,09430,72236,85542,19447,81353,38447,41151,366-123,674-118,471-113,339000
   Common Stock
0
0
0
664
1,130
1,412
5
5
5
5
5
5
5
5
5
5
55555555551,4121,130664000
   Retained Earnings Total Equity000-47,291-38,919-30,133-22,178-14,5540-3,142000000
   Accumulated Other Comprehensive Income -12-41-63-10-73-57000-136,958000000
   Capital Surplus 
0
0
0
0
0
10
54,503
0
67,933
69,986
72,379
75,842
78,018
0
0
0
00078,01875,84272,37969,98667,933054,5031000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
54,503
55,737
67,933
69,986
72,379
75,842
78,018
80,746
83,380
85,762
85,76283,38080,74678,01875,84272,37969,98667,93355,73754,503000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-822
Gross Profit-822-822
 
Operating Income (+$)
Gross Profit-822
Operating Expense-65,277
Operating Income-66,099-66,099
 
Operating Expense (+$)
Research Development39,624
Selling General Administrative26,475
Selling And Marketing Expenses822
Operating Expense65,27766,921
 
Net Interest Income (+$)
Interest Income3,444
Interest Expense-5,085
Other Finance Cost-577
Net Interest Income-1,064
 
Pretax Income (+$)
Operating Income-66,099
Net Interest Income-1,064
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-67,883-64,315
EBIT - interestExpense = -71,184
-67,883
-28,885
Interest Expense5,085
Earnings Before Interest and Taxes (EBIT)-66,099-62,798
Earnings Before Interest and Taxes (EBITDA)-65,277
 
After tax Income (+$)
Income Before Tax-67,883
Tax Provision--41
Net Income From Continuing Ops-71,170-67,842
Net Income-33,970
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses66,099
Total Other Income/Expenses Net-1,7841,064
 

Technical Analysis of Rani Therapeutics Holdings Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rani Therapeutics Holdings Inc. The general trend of Rani Therapeutics Holdings Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rani Therapeutics Holdings Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rani Therapeutics Holdings Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.331 < 8.75 < 8.99.

The bearish price targets are: 6.38 > 5.81 > 5.79.

Tweet this
Rani Therapeutics Holdings Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rani Therapeutics Holdings Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rani Therapeutics Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rani Therapeutics Holdings Inc. The current macd is 0.85800956.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rani Therapeutics Holdings Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rani Therapeutics Holdings Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rani Therapeutics Holdings Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Rani Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartRani Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rani Therapeutics Holdings Inc. The current adx is 39.65.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Rani Therapeutics Holdings Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Rani Therapeutics Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rani Therapeutics Holdings Inc. The current sar is 8.650604.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Rani Therapeutics Holdings Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rani Therapeutics Holdings Inc. The current rsi is 63.32. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Rani Therapeutics Holdings Inc Daily Relative Strength Index (RSI) ChartRani Therapeutics Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rani Therapeutics Holdings Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rani Therapeutics Holdings Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Rani Therapeutics Holdings Inc Daily Stochastic Oscillator ChartRani Therapeutics Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rani Therapeutics Holdings Inc. The current cci is 58.57.

Rani Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) ChartRani Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rani Therapeutics Holdings Inc. The current cmo is 23.18.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Rani Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartRani Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rani Therapeutics Holdings Inc. The current willr is -41.83673469.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Rani Therapeutics Holdings Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Rani Therapeutics Holdings Inc Daily Williams %R ChartRani Therapeutics Holdings Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rani Therapeutics Holdings Inc. The current atr is 0.70687421.

Rani Therapeutics Holdings Inc Daily Average True Range (ATR) ChartRani Therapeutics Holdings Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rani Therapeutics Holdings Inc. The current obv is 3,669,499.

Rani Therapeutics Holdings Inc Daily On-Balance Volume (OBV) ChartRani Therapeutics Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rani Therapeutics Holdings Inc. The current mfi is 78.52.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Rani Therapeutics Holdings Inc Daily Money Flow Index (MFI) ChartRani Therapeutics Holdings Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rani Therapeutics Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Rani Therapeutics Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rani Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5063.320
Ma 20Greater thanMa 505.478
Ma 50Greater thanMa 1004.234
Ma 100Greater thanMa 2003.778
OpenGreater thanClose6.610
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rani Therapeutics Holdings Inc with someone you think should read this too:
  • Are you bullish or bearish on Rani Therapeutics Holdings Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rani Therapeutics Holdings Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rani Therapeutics Holdings Inc

I send you an email if I find something interesting about Rani Therapeutics Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Rani Therapeutics Holdings Inc.

Receive notifications about Rani Therapeutics Holdings Inc in your mailbox!